{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:52:45Z","timestamp":1784307165322,"version":"3.55.0"},"reference-count":100,"publisher":"Termedia Sp. z.o.o.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatologia"],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by joint inflammation, degradation of cartilage and bone, and potential systemic effects. This paper provides a comprehensive historical overview of RA treatment, tracing the evolution from ancient empirical methods to modern targeted therapies.\nAdvancements in the understanding of RA\u2019s immunopathology have led to the development of conventional, biological, and targeted disease-modifying antirheumatic drugs, including tumor necrosis factor \uf061 inhibitors and Janus kinase inhibitors. These innovations have been pivotal in transforming RA management, allowing for more personalized and effective treatment strategies.\nThe historical progression in RA treatment reflects a shift from symptomatic management to targeted interventions aimed at the underlying mechanisms of the disease. This shift has not only improved clinical outcomes but also enhanced the quality of life for those affected by RA, underscoring the importance of ongoing research and adaptation of therapeutic strategies.<\/jats:p>","DOI":"10.5114\/reum\/195012","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:25:44Z","timestamp":1740144344000},"source":"Crossref","is-referenced-by-count":5,"title":["Evolving strategies in the treatment of rheumatoid arthritis: a historical perspective"],"prefix":"10.5114","author":[{"given":"Julia","family":"Doma\u0144ska-Pobo\u017ca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5981-6041","authenticated-orcid":true,"given":"Ma\u0142gorzata","family":"Wis\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"ref-1391549","doi-asserted-by":"publisher","DOI":"10.7326\/AITC201901010"},{"key":"ref-1391550","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366"},{"key":"ref-1391551","doi-asserted-by":"publisher","DOI":"10.1016\/s1297-319x(00)00247-5"},{"key":"ref-1391552","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.08.001"},{"key":"ref-1391553","unstructured":"Benedek TG. History of the development of corticosteroid therapy. Clin Exp Rheumatol 2011; 29 (5 Suppl 68): S5\u2013S12."},{"key":"ref-1391554","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223443"},{"key":"ref-1391555","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2007285117"},{"key":"ref-1391556","unstructured":"Gold Preparations. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; August 2, 2017."},{"key":"ref-1391557","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108272"},{"key":"ref-1391558","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199550010-00009"},{"key":"ref-1391559","doi-asserted-by":"crossref","unstructured":"Smedeg\u00e5rd G, Bj\u00f6rk J. Sulphasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl 2: 7\u201315.","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.7"},{"key":"ref-1391560","unstructured":"Sulfasalazine in early rheumatoid arthritis. The Australian Multicentre Clinical Trial Group. J Rheumatol 1992; 19: 1672\u20131677."},{"key":"ref-1391561","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565130-00008"},{"key":"ref-1391562","unstructured":"Segal R, Caspi D, Sukenik S, et al. Sulfasalazine in rheumatoid arthritis. Harefuah 1991; 120: 577\u2013581 [Article in Hebrew]."},{"key":"ref-1391563","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0372-x"},{"key":"ref-1391564","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"ref-1391565","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.058"},{"key":"ref-1391566","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.07.004"},{"key":"ref-1391567","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X11408635"},{"key":"ref-1391568","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes122"},{"key":"ref-1391569","unstructured":"Bannwarth B, Schaeverbeke T, Labat L, et al. Side-effects during treatment of rheumatoid arthritis with methotrexate. Rev Rhum Ed Fr 1994; 61: 337\u2013342 [Article in French]."},{"key":"ref-1391570","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15839"},{"key":"ref-1391571","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2017.07.020"},{"key":"ref-1391572","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958060-00010"},{"key":"ref-1391573","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.101482"},{"key":"ref-1391574","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052719"},{"key":"ref-1391575","doi-asserted-by":"publisher","DOI":"10.3892\/br.2012.42"},{"key":"ref-1391576","unstructured":"Gerriets V, Goyal A, Khaddour K. Tumor Necrosis Factor Inhibitors. [Updated 2023 Jul 3]. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL) 2024. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482425\/."},{"key":"ref-1391577","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0829-7"},{"key":"ref-1391578","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep329"},{"key":"ref-1391579","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001293"},{"key":"ref-1391580","doi-asserted-by":"publisher","DOI":"10.1002\/art.22033"},{"key":"ref-1391581","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068064"},{"key":"ref-1391582","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-"},{"key":"ref-1391584","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key361"},{"key":"ref-1391585","doi-asserted-by":"publisher","DOI":"10.14740\/jmc3902"},{"key":"ref-1391586","unstructured":"Bonnefoy-Berard N, Besnard V, Morel P, et al. Second signal for T lymphocyte activation: multiple targets for pharmacological modulation. Dev Biol Stand 1992; 77: 41\u201348."},{"key":"ref-1391587","doi-asserted-by":"publisher","DOI":"10.1021\/bi900853v"},{"key":"ref-1391588","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1989"},{"key":"ref-1391589","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.5.9.1245"},{"key":"ref-1391590","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750753"},{"key":"ref-1391591","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-015-0016-9"},{"key":"ref-1391592","unstructured":"Hanif N, Anwer F. Rituximab. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available at: https: \/\/www.ncbi.nlm.nih.gov\/books\/NBK564374\/."},{"key":"ref-1391593","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2020.1770948"},{"key":"ref-1391594","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031246"},{"key":"ref-1391595","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224049"},{"key":"ref-1391596","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19255"},{"key":"ref-1391597","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218460"},{"key":"ref-1391598","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204154"},{"key":"ref-1391599","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/516593"},{"key":"ref-1391600","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.631291"},{"key":"ref-1391601","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.8343"},{"key":"ref-1391602","doi-asserted-by":"publisher","DOI":"10.3390\/biotech10030011"},{"key":"ref-1391603","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.1c00245"},{"key":"ref-1391604","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-022-00997-x"},{"key":"ref-1391605","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031337"},{"key":"ref-1391606","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(99)05246-0"},{"key":"ref-1391607","doi-asserted-by":"publisher","DOI":"10.1002\/art.21678"},{"key":"ref-1391608","doi-asserted-by":"publisher","DOI":"10.1002\/art.10308"},{"key":"ref-1391609","doi-asserted-by":"publisher","DOI":"10.1002\/art.21655"},{"key":"ref-1391610","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61000-4"},{"key":"ref-1391611","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"ref-1391612","doi-asserted-by":"publisher","DOI":"10.1002\/art.21519"},{"key":"ref-1391613","unstructured":"Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563\u20132571."},{"key":"ref-1391614","doi-asserted-by":"publisher","DOI":"10.1002\/art.23964"},{"key":"ref-1391615","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101659"},{"key":"ref-1391616","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204632"},{"key":"ref-1391617","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207511"},{"key":"ref-1391618","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209057"},{"key":"ref-1391619","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60506-7"},{"key":"ref-1391620","doi-asserted-by":"publisher","DOI":"10.1002\/art.24638"},{"key":"ref-1391621","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.116319"},{"key":"ref-1391622","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050524"},{"key":"ref-1391623","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-12-200606200-00003"},{"key":"ref-1391624","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206106"},{"key":"ref-1391625","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02650-8"},{"key":"ref-1391626","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"ref-1391627","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092866"},{"key":"ref-1391628","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105197"},{"key":"ref-1391629","doi-asserted-by":"publisher","DOI":"10.1002\/art.30158"},{"key":"ref-1391630","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207628"},{"key":"ref-1391631","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025"},{"key":"ref-1391632","unstructured":"Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. J Rheumatol 2008; 35: 20\u201330."},{"key":"ref-1391633","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137703"},{"key":"ref-1391634","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1856-4"},{"key":"ref-1391635","doi-asserted-by":"publisher","DOI":"10.1002\/art.39944"},{"key":"ref-1391636","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210310"},{"key":"ref-1391637","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"ref-1391638","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23004"},{"key":"ref-1391639","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"ref-1391640","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"ref-1391641","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"ref-1391642","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"ref-1391643","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2059-8"},{"key":"ref-1391644","doi-asserted-by":"publisher","DOI":"10.1002\/art.39953"},{"key":"ref-1391645","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"ref-1391646","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210094"},{"key":"ref-1391647","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"ref-1391648","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055"},{"key":"ref-1391649","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219213"}],"container-title":["Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/reu.termedia.pl\/pdf-195012-122736","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reu.termedia.pl\/pdf-195012-122736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:25:59Z","timestamp":1740144359000},"score":1,"resource":{"primary":{"URL":"https:\/\/reu.termedia.pl\/Evolving-strategies-in-the-treatment-of-rheumatoid-arthritis-a-historical-perspective,195012,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":100,"alternative-id":["195012"],"URL":"https:\/\/doi.org\/10.5114\/reum\/195012","relation":{},"ISSN":["0034-6233","2084-9834"],"issn-type":[{"value":"0034-6233","type":"print"},{"value":"2084-9834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]}}}